The three funds in the Franklin Allocator series--Franklin Growth Allocation, Franklin Moderate Allocation, and Franklin Conservative Allocation--have undergone notable changes in recent years, and the most recent ones substantially lowered costs. But it's still not clear the funds are positioned for success. The funds earn Morningstar Analyst Ratings of Neutral across all share classes.
Franklin Growth Allocation C FTGTX
NAV / 1-Day Return
19.50
/
1.93
%
Total Assets
1.4 Bil
Adj. Expense Ratio
Adjusted Expense Ratio excludes certain variable investment-related expenses, such as interest from borrowings and dividends on borrowed securities, allowing for more consistent cost comparisons across funds.
1.690%
Expense Ratio
1.690%
Fee Level
Average
Longest Manager Tenure
9.17
years
Category
Allocation--70% to 85% Equity
Investment Style
Large BlendCredit Quality / Interest Rate Sensitivity
—Status
Open
TTM Yield
0.55%
Turnover
64%
Premium
Morningstar’s Analysis
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
Will FTGTX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
Process Pillar
The Process Pillar is our assessment of how sensible, clearly defined, and repeatable FTGTX’s performance objective and investment process is for both security selection and portfolio construction.
People Pillar
The People Pillar is our evaluation of the FTGTX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of FTGTX’s parent organization’s priorities and whether they’re in line with investors’ interests.
The latest changes to this ever-evolving target-risk series are positive, but it’s still not compelling.
